Alimera’s Iluvien receives positive funding recommendation

The U.K.’s National Institute of Health and Care Excellence has recommended funding for Iluvien as treatment for noninfectious posterior uveitis, Alimera announced.
With this recommendation, the U.K.’s National Health Service will pay for prescriptions for the fluocinolone acetonide intravitreal implant 0.19 mg treatment of noninfectious uveitis affecting the posterior segment, according to the company press release.
Iluvien is also indicated for and funded for the treatment of diabetic macular edema in the U.K.
“We continue to execute on our plans to launch Iluvien’s new

Full Story →